US2021040260A1PendingUtilityA1
Nanoparticles
Est. expiryJul 18, 2034(~8 yrs left)· nominal 20-yr term from priority
C08G 61/02C08G 2261/411B82Y 30/00C08G 61/123C08J 3/12C08G 61/126C08G 2261/3223C08G 61/122C08G 2261/414C08G 2261/94C08K 5/01C08G 2261/3142C08G 2261/91C08G 2261/364C08G 2261/3162C08G 2261/1424C08G 2261/148C08G 2261/524C08G 2261/344C09K 11/06C08G 2261/312C09K 2211/1483C08G 2261/314C08G 2261/135C09K 2211/1416C08G 2261/90C08L 65/00C08G 2261/1426C08J 2365/00C09K 11/025C09K 2211/1458C08G 2261/92C08G 61/12C09K 2211/1425C08G 2261/374C08G 2261/522C08G 2261/18C08G 2261/3246C09K 2211/1466C09K 2211/1433C08G 2261/37C09K 2211/185C08G 2261/124C09K 2211/188C08G 2261/1412C08G 2261/228
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Nanoparticle compositions comprising nanoparticles formed from π-conjugated cross-linked polymers are disclosed, together with their methods of manufacture and their applications. Owing to the nature of the cross-links formed therein, the nanoparticle compositions afford a high degree of manufacturing flexibility and control, as well as being amenable to facile purification for the purpose of imaging and electronics applications.
Claims
exact text as granted — not AI-modified1 .- 26 . (canceled)
27 . A nanoparticle composition comprising a plurality of nanoparticles formed from a π-conjugated cross-linked polymer, the π-conjugated cross-linked polymer comprising
a) 80-99.9 mol. % of π-conjugated monomers, and
b) 0.1-20 mol. % of a cross-linker having the formula I shown below:
wherein
Z 1 and Z 2 are monomeric moieties,
Y is absent, a bond, or a linking group; and
wherein the π-conjugated monomers comprise a moiety having the formula IV shown below:
wherein
R 1 and R 2 are each independently a group:
—X-Q
wherein
X is selected from the group consisting of (1-30C)alkylene, (2-30C)alkenylene, (2-30C)alkynylene, —[O—(CH 2 ) 2 ] n —, —(CH 2 ) m (CF 2 ) n —, and —[O—Si(R z ) 2 ] n —, wherein R z is (1-4C)alkyl, n is 1 to 30, and m is 0 to 30); and
Q is a terminal group selected from hydroxyl, carboxyl, amino, —C═CH 2 , —C≡CH, —SH, -biotin, -streptavidin and epoxy.
28 . The nanoparticle composition of claim 27 , wherein X is (1-30C)alkylene and Q is carboxyl or amino.
29 . The nanoparticle composition of claim 27 , wherein the π-conjugated monomers comprise a moiety having the formula:
30 . The nanoparticle composition of claim 27 , wherein the π-conjugated monomers further comprise one or more of the following moieties:
wherein R 3 and R 4 are each independently a group:
—X 1 -Q 1
wherein
X 1 is selected from the group consisting of (1-30C)alkylene, (2-30C)alkenylene, (2-30C)alkynylene, —[(CH 2 ) 2 —O] n —, —[O—(CH 2 ) 2 ] n —, —(CH 2 ) m (CF 2 ) n —, and —[O—Si(R z ) 2 ] n —, wherein R z is (1-4C)alkyl, n is 1 to 30, and m is 0 to 30); and
Q 1 is a terminal group selected from hydrogen, methyl, hydroxyl, carboxyl, (1-4C)alkoxycarbonyl, amino, —C═CH 2 , —C≡CH, —SH, -biotin, -streptavidin, —CF 3 , and a polymerisable group selected from acrylates, epoxy and styrene;
M is a metal selected from Ir, Pt, Rh, Re, Ru, Os, Cr, Cu, Pd and Au;
L is a ligand independently selected from the group consisting of halo, (1-30C)hydrocarbyl optionally comprising one or more heteroatoms selected from N, O, S, Si or P, or an aryl or heteroaryl group optionally substituted with one or more substituents selected from (1-4C)alkyl, halo, aryl or heteroaryl; and
p is 1 to 4.
31 . The nanoparticle composition of claim 30 , wherein
X 1 is selected from the group consisting of (1-20C)alkylene, —[(CH 2 ) 2 —O] n — or —[O—(CH 2 ) 2 ] n — (wherein n is 1 to 20); Q 1 is a terminal group selected from hydrogen, methyl, (1-2C)alkoxycarbonyl and hydroxyl; M is Ir; L is a ligand independently selected from the group consisting of aryl or heteroaryl, optionally substituted with one or more substituents selected from aryl or heteroaryl; and p is 1 to 2.
32 . The nanoparticle composition of claim 30 , wherein
X 1 is selected from the group consisting of (4-12C)alkylene or —[(CH 2 ) 2 —O] n — (wherein n is 1 to 15); Q 1 is a terminal group selected from hydrogen, (1-2C)alkoxycarbonyl and methyl; M is Ir; L is a ligand independently selected from the group consisting of phenyl or 6-membered heteroaryl, optionally substituted with one or more substituents selected from phenyl or 6-membered heteroaryl; and p is 1 to 2.
33 . The nanoparticle composition of claim 30 , wherein the π-conjugated monomers further comprise one or more of the following moieties:
34 . The nanoparticle composition of claim 27 , wherein the cross-linker has the formula II shown below:
wherein
Y is absent, a bond, or a linking group.
35 . The nanoparticle composition of claim 34 , wherein the cross linker has the formula III shown below:
36 . The nanoparticle composition of claim 34 , wherein the cross-linker has the following structure:
37 . A method of forming a nanoparticle composition as claimed in claim 27 , the method comprising the step of forming the nanoparticles by emulsion polymerisation, miniemulsion polymerisation or dispersion polymerisation techniques to provide an aqueous suspension of nanoparticles.
38 . The method of claim 37 , wherein the nanoparticles are formed by a cross-coupling polymerisation reaction.
39 . The method of claim 38 , wherein the polymerisation reaction is a Suziki reaction.
40 . The method of claim 38 , wherein the polymerisation reaction is a Stille reaction.
41 . The method of claim 38 , further comprising the step of purifying the aqueous suspension of nanoparticles.
42 . The method of claim 41 , wherein the aqueous suspension of nanoparticles is purified by contacting the aqueous suspension of nanoparticles with at least one organic solvent.
43 . The method of claim 42 , wherein the at least one organic solvent is selected from the group consisting of polar and non-polar solvents.
44 . The method of claim 43 , wherein the at least one organic solvent is methanol.
45 . Use of a nanoparticle composition as defined in claim 27 in one or more applications selected from the group consisting of biological or non-biological imaging or sensing, down-conversion of LED light, anti-counterfeit encoding, displays, cell-sorting/flow cytometry, long-term cell tracking, and flow visualisation.
46 . A nanoparticle dispersion comprising a nanoparticle composition as claimed in claim 27 dispersed throughout a dispersing medium.Join the waitlist — get patent alerts
Track US2021040260A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.